What is ESOMER?

ESOMER is a drug, which due to a specific mechanism of action reduces the intensity of acid secretion in the stomach


Esomeprazole - 20 mg

Esomeprazole - 40 mg

The active substance of the drug EZOMER - esomeprazole - S-isomer of omeprazole, reduces the secretion of acid in the stomach due to a specific target mechanism of action. It is a specific inhibitor of acid pumps in parietal cells. The R- and S-isomers of omeprazole have similar pharmacodynamic activity. Esomeprazole is a weak base, and in an extremely acidic environment in which the secretory tubules of parietal cells are located, its concentration is increased and converted into an active form that inhibits the activity of the H + / K + -ATPase enzyme-acid pump, and also inhibits both basal and stimulated acid secretion

  • Powerful antisecretory effect
  • Synergy with antibiotics in the complex treatment of Helicobacter pylori infection
  • Possibility of application once a day
  • Treatment of erosive reflux esophagitis
  • Long-term treatment of patients with cured esophagitis for the prevention of recurrence
  • Symptomatic treatment of gastroesophageal reflux disease
  • In combination with appropriate antibiotic treatment regimens for destruction of Helicobacter pylori
  • Treatment of duodenal ulcers caused by Helicobacter pylori
  • Prevention of recurrence of gastric ulcers and duodenal ulcers in patients with ulcers caused by Helicobacter pylori
  • Treatment and prevention of recurrences of gastric and duodenal ulcers caused by the use of NSAIDs
  • Zollinger-Ellison syndrome

Gastroesophageal reflux:
- Treatment of erosive reflux esophagitis: 40 mg once daily for 4 weeks. For patients in whom esophagitis is not cured or symptoms of the disease, an additional 4-week treatment is recommended
- Long-term treatment of patients with cured esophagitis for the prevention of recurrence: 20 mg once a day daily
- Symptomatic treatment of gastroesophageal reflux: patients without esophagitis - 20 mg once a day daily. If the symptoms do not disappear after 4 weeks, an additional examination of the patient should be performed. If the symptoms have disappeared, then for further monitoring, you can apply 20 mg daily. In adults,the treatment regimen is used as necessary, usually 20 mg once a day. To further control the symptoms in patients undergoing treatment by NSAIDs with reported increased risk of developing gastric and duodenal ulcers, it is not recommended to apply the "on-demand" treatment regimen
In combination with appropriate antibiotic treatment regimens for destruction Helicobacter pylori:
- 20 mg of EZOMER in a complex with 1 g of amoxicillin and 500 mg of clarithromycin twice a day for 7 days
Treatment and prevention of gastric and duodenal ulcers caused by the use of NSAIDs:
- The usual dose is 20 mg once a day
Treatment for Zollinger-Ellison syndrome:
- The recommended initial dose is 40 mg twice a day. Later the dose can be individually changed and continue treatment according to clinical indications

From the digestive system: often - abdominal pain, constipation, diarrhea, flatulence, nausea / vomiting; infrequently - dry mouth; rarely - stomatitis, gastrointestinal candidiasis
From the hepatobiliary system: infrequently - increased activity of liver enzymes; rarely - hepatitis with or without jaundice; very rarely - liver failure, encephalopathy in patients with a previous liver disease
From the skin and subcutaneous tissues: infrequently - dermatitis, itching, rash, hives; rarely - baldness, photosensitivity; very rarely - erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis
From the nervous system: often - headache; infrequently - dizziness, paresthesia, drowsiness; rarely - a violation of taste

Children under 12 years; hypersensitivity to the active substance, substituted benzimidazoles or any other ingredient of the drug. Esomeprazole, like other inhibitors of the proton pump, is not recommended for use with atazanavir

Patients undergoing long-term treatment (especially with treatment for more than one year) should be monitored regularly
In the presence of any anxiety symptom (for example, a significant unintentional reduction in body weight, frequent vomiting, dysphagia, bloody vomit or melena), and if there is or suspected stomach ulcer, a malignant disease should be ruled out, as treatment with esomeprazole may mask symptoms and delay detection of the tumor
Use during pregnancy or lactation. Obtained insufficient clinical data on the effects of esomeprazole during pregnancy. When using omeprazole, which is a racemic mixture, the data obtained during epidemiological studies for more women during pregnancy do not indicate the presence of effects associated with malformation or fetotoxicity. During animal experiments with esomeprazole, no data were obtained that would indicate a harmful effect on the development of the embryo / fetus. During animal experiments using this racemic mixture, there were no signs of direct or indirect adverse effects on the course of pregnancy, childbirth or postnatal development. Prescribe this drug to pregnant women with caution. Until now, it is not known whether esomeprazole penetrates breast milk in women. Studies involving women during lactation were not conducted. Therefore, the drug is not recommended for use during breastfeeding
Children. Due to the lack of data, the drug is not recommended for the treatment of children under the age of 12 years. The ability to influence the reaction rate when driving vehicles or working with other mechanisms. No impact was found

Store in a dark place at a temperature not above 25 °C. Keep out of the reach of children!

Gastro-resistant tablets, 14 tablets

Gastro-resistant tablets, 28 tablets

Powder for solution for injection in ampoules, 10 ampoules of 40 mg each

By prescription